GLP-1 receptor agonists liraglutide and exenatide reduced neurological damage and inhibited NAFLD and cardiomyocyte pyroptosis in diabetic rats by inhibiting NLRP3 inflammasome activation (212–215); Similarly, exendin-4 also inhibited the activation of NLRP3 under HG conditions and alleviated cardiomyocyte pyroptosis (181). This evidence concerns the gene NLRP3 and metabolic dysfunction-associated steatotic liver disease.